Back to News & Events

Immunovent Wins “Best of the Best” in 1st Pitch Life Science Competition

Immunovent, a New York City based diagnostic start-up focusing on the commercialization of novel technologies for diagnosing allergies, was chosen as the “Best of the Best” among previous winners of Mid-Atlantic Bio Angels (MABA)1st Pitch Life Science events in 2014. Seven companies competed for the title of ?Best of the Best?.

Immunovent is developing a platform technology called the Local Antibody Mucosal Brush Diagnostic (LAMB-Dx). It is a needle-free allergy test that works with minute cell samples that are easily and painlessly collected with a soft brush. A proprietary process is then used to detect the specific proteins in the samples that indicate the presence of a food or airborne allergy.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4906
                    [post_author] => 4
                    [post_date] => 2025-07-17 10:27:09
                    [post_date_gmt] => 2025-07-17 14:27:09
                    [post_content] => 

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.

The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.

“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”

Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.

“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.

As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.

Dowload the full press release here.

[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => redesignation2025 [to_ping] => [pinged] => [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4906 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4389 [post_author] => 4 [post_date] => 2024-02-26 12:22:02 [post_date_gmt] => 2024-02-26 17:22:02 [post_content] =>

The Center for Biotechnology has announced a Call for Proposals for our 2024 Applied Research and Development (ARAD) Program. The ARAD program provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology.

These areas include research technologies, diagnostics, therapeutics and medical devices. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.

2024 Proposal Submission:
The deadline for receipt of applications is May 15, 2024, 5pm. No exceptions will be made. Applications are accepted and considered on a competitive basis and are subject to the availability of funds. Approval from the Research Foundation Sponsored Programs is not required prior to submission, but will be required if the project is selected for funding. All applications require a letter-of-support from a senior executive of the company confirming their corporate residency in New York State and financial commitment to match-fund the project. Further details are found within the forms pages. A single PDF version of the proposal and letter of support should be submitted to the Center for Biotechnology at center_for_biotechnology@stonybrook.edu.

ARAD Program Forms:

Call for Applications & Guidelines

Application Form

Budget Forms

[post_title] => Call for Proposals: Applied Research and Development Program 2024 [post_excerpt] => 2024 Applied Research and Development (ARAD) Program RFP Released! The ARAD program provides matching funds on a support collaborations between Stony Brook University faculty and NY State corporate partners. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => arad-2024 [to_ping] => [pinged] => [post_modified] => 2024-05-13 10:38:27 [post_modified_gmt] => 2024-05-13 14:38:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4389 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 1428 [post_author] => 3 [post_date] => 2015-03-02 17:06:37 [post_date_gmt] => 2015-03-02 17:06:37 [post_content] => The Entrepreneur's Toolkit Workshop is the next installment of how to workshops for entrepreneurs, early phase companies, inventors, and anyone thinking of becoming an entrepreneur. Technology agnostic information on topics such as Seed Funding, Crowd Funding, What is the profile of a fundable company? Protecting my edge in intellectual property? What type of incorporation is right for me? will be presented. View complete agenda here. This event will be taking place April 21, 2015 at the Center for Wireless and Information Technology at Stony Brook University. View event flyer - Registration for this singular event is at no charge, but space is limited - please reserve your seat here: http://www.cewit.org/newsevents/EntrepreneursToolkitInterestForm.html [post_title] => The Entrepreneur's Toolkit Workshop - April 21, 2015 [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => the-entrepreneurs-toolkit-workshop-april-21-2015 [to_ping] => [pinged] => [post_modified] => 2016-03-02 17:59:51 [post_modified_gmt] => 2016-03-02 17:59:51 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1428 [menu_order] => 212 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 2064 [post_author] => 3 [post_date] => 2015-12-07 20:15:00 [post_date_gmt] => 2015-12-07 20:15:00 [post_content] => Accelerating Biomedical Discoveries for Commercialization STONY BROOK, N.Y. – December 7, 2015 - The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced today the recipients of the first technology development grants awarded by the Hub. Thirteen awards totaling $900,000 were granted to applicants from Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory. The LIBH technology development grants are a multi-tiered funding initiative aimed at collectively contributing to a pipeline of commercially promising biomedical technology in the region. The three funding initiatives include Feasibility, Proof of Concept and Commercialization awards. Feasibility awards are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications of an existing technology.  Proof of Concept Awards provide targeted, milestone driven support for proof of concept research, development, testing, and analysis of existing intellectual property. The final tier, Commercialization Awards, provide targeted, milestone-driven support for a subset of projects with existing intellectual property where additional investment will clearly advance the technology to a major value inflection point for commercialization. The grants awarded this cycle will support technologies developed across multiple disciplines including pharmacology, biomedical engineering, chemistry, and microbiology. Among the award recipients were two post-doctoral researchers. Of the thirteen grants awarded, eight were Feasibility awards and five were Proof of Concept Awards. The recipients of this round of awards are: Feasibility awards
  • Targeting Pathogenic Viral Infections with First-In-Class Viral Budding Inhibitors - Dr. Carol Carter
  • Development of Small Molecule Inhibitors for PLD6 as Therapeutics for Triple Negative Breast Cancer - Dr. Michael Frohman
  • Novel miR-129 Based Therapeutics for Colon Cancer - Dr. Jingfang Ju
  • Fast Hybrid Approach For Determination of Structure of Therapeutic Protein Complexes - Dr. Dima Kosakov
  • Enhancement of Protein Yields Using Mechanical Signals: Augmenting Biotech Production to Reduce Drug Costs - Dr. Gabriel Pagnotti
  • Non-invasive Acoustic Radiation Force Therapy for OA Induced Pain and Cartilage Regeneration - Dr. Yixian Qin
  • LDL as Biomarker for Childhood Tuberculosis (TB) - Dr. Xinxin Yang
Proof of Concept awards
  • A New Standard of Care for Implant Bed Preparation Utilizing an Innovative Drill Bit Technology - Dr. Marcous Abboud
  • Orthovoltage X-Ray Minibeams: Brain Tumor Therapy with Tissue-sparing Incident Beams - Dr. Avraham Dilmanian
  • NEW‐HARP: A Highly Sensitive Avalanche Selenium Detector for Time‐of‐Flight (TOF) Positron Emission Tomography (PET) - Dr. Amirhossein Goldan
  • Azasteroids for Combination Anti-TB Therapy - Dr. Nicole Sampson
  • A Novel Glioblastoma Drug – Oncolytic Virus PV1-Mono-Cre - Dr. Eckard Wimmer
​“We are excited to see such a robust and diverse portfolio of early stage technologies supported through the LIBH and NIH-REACH consortium,” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “We are hopeful that this investment by the federal and state government, as well as SBU, CSHL and BNL, will foster and accelerate the translation of these technologies from the bench to the bed side, and help attract further investment from the industrial and financial sectors.” The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission. [post_title] => Long Island Bioscience Hub Announces Funded Projects [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-bioscience-hub-announces-funded-projects [to_ping] => [pinged] => [post_modified] => 2016-03-29 20:18:36 [post_modified_gmt] => 2016-03-29 20:18:36 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2064 [menu_order] => 195 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 5 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4906 [post_author] => 4 [post_date] => 2025-07-17 10:27:09 [post_date_gmt] => 2025-07-17 14:27:09 [post_content] =>

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.

The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.

“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”

Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.

“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.

As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.

Dowload the full press release here.

[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => redesignation2025 [to_ping] => [pinged] => [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4906 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 281 [max_num_pages] => 94 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology

More Information

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Call for Proposals: Applied Research and Development Program 2024

More Information

The Entrepreneur’s Toolkit Workshop – April 21, 2015

More Information

Long Island Bioscience Hub Announces Funded Projects

More Information